RBC keeps USD 1,500 target for Eli Lilly and Co. stock
Published on 10/14/2026 at 12:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and pipeline data
- Royal Bank of Canada reissued an Outperform rating and USD 1,500.00 target on October 14, 2026.
- Eli Lilly reported USD 22.97 billion of Q2 2026 revenue, up 48.00 percent year over year.
- Eli Lilly and Co. stock traded at EUR 1,047.00 at 12:31 p.m. CEST on October 14, 2026.
Eli Lilly and Co. (ISIN US5324571083) traded at EUR 1,047.00 at Lang & Schwarz at 12:31 p.m. CEST on October 14, 2026, 5.42 percent below its 52-week high of EUR 1,107.00. As The Stock Observer reported on October 14, 2026, Royal Bank of Canada reissued an Outperform rating and a USD 1,500.00 price target for the company. The target is a separate valuation signal from the euro quote, not a forecast made in this article.
Clinical data add a new angle
On October 9, 2026, Eli Lilly released exploratory Phase 3b data from the TOGETHER-PsO study of Taltz and Zepbound in adults with psoriasis and obesity or overweight. The analysis covered 274 randomized participants.
The combination produced broader biomarker responses than Taltz alone by Week 36, including changes in 482 proteins versus 140 and 467 genes versus 16. The figures support a broader immunometabolic development story, although they are biomarker results rather than a new approval or revenue contribution.
Revenue growth meets pricing pressure
In the second quarter of 2026, revenue reached USD 22.97 billion, up 48.00 percent from the second quarter of 2025, according to Benzinga. Non-GAAP earnings per share were USD 8.38 in the quarter, including USD 3.03 per share of acquired in-process research and development charges.
Management also raised its full-year 2026 revenue guidance to USD 85.00 billion to USD 87.00 billion and its non-GAAP performance margin guidance to 49.00 percent to 50.50 percent. The same call said U.S. prices declined 9.00 percent after excluding favorable rebate and discount estimate adjustments, creating a counterweight to volume-led growth.
Upcoming earnings date
Eli Lilly lists its third-quarter 2026 earnings call for October 29, 2026, at 10:00 a.m. EDT. That report will give investors a fresh test of whether prescription volume can offset pricing pressure after the second-quarter revenue increase.
Three recent company milestones
On October 5, 2026, Lilly said it would present 21 dermatology data presentations at Fall Clinical 2026. On October 8, 2026, the company discussed second-quarter revenue growth of 48.00 percent and full-year revenue guidance of USD 85.00 billion to USD 87.00 billion during its earnings call. On October 9, 2026, the TOGETHER-PsO release added the 274-participant clinical data update.
What does the valuation show
The Lang & Schwarz quote of EUR 1,047.00 sits 5.42 percent below the EUR 1,107.00 52-week high and implies a market capitalization of EUR 985.8 billion as of October 14, 2026. Royal Bank of Canada's USD 1,500.00 target uses a different currency and therefore is not converted into a euro percentage comparison.
Price and trading context
Eli Lilly and Co. was trading at EUR 1,047.00 at Lang & Schwarz on October 14, 2026, at 12:31 p.m. CEST. The 52-week range in the euro quote was EUR 662.90 to EUR 1,107.00, with the current price 5.42 percent below the upper end.
The further course of trading is shown by the continuously updated real-time quote of Eli Lilly and Co. stock.
Eli Lilly and Co. stock facts
- Company: Eli Lilly and Company
- ISIN: US5324571083
- Ticker: LLY
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 14, 2026, 12:31 p.m. CEST): EUR 1,047.00
- Market capitalization: EUR 985.8 billion (as of October 14, 2026)
- 52-week range: EUR 662.90-1,107.00 (as of October 14, 2026)
- Next earnings date: October 29, 2026
Market context: Market report S&P 500.
